Chitosan-coated solid lipid nanoparticles for nose-to-brain drug delivery: A comprehensive review
DOI:
https://doi.org/10.69857/joapr.v14i2.2072Keywords:
Nose to brain delivery, chitosan-coated solid lipid nanoparticles, Intranasal drug delivery, Mucoadhesion, Nanomedicine, CNS disordersAbstract
Background: The blood-brain barrier (BBB) limits the effectiveness of treatment of several central nervous system (CNS) diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, and bipolar disorder. Because of this limitation, intranasal drug delivery is an effective, non-invasive way to bypass the BBB via the olfactory and trigeminal pathways. Methodology: In this review, we critically evaluate the design, characterization, mechanism of action, and potential therapeutic use of Chitosan-coated Solid Lipid Nanoparticles (SLNs) as a delivery system for drugs from the nasal cavity to the brain. A structured literature search was conducted in PubMed, Scopus, and Web of Science for studies published between 2019 and 2025 using keywords related to chitosan-coated solid lipid nanoparticles and nose-to-brain delivery. Studies reporting pharmacokinetic parameters, such as brain AUC, brain-targeting efficiency (BTE%), and drug-targeting index (DTI), were included. Results and Discussion: Preclinical studies show that some chitosan-coated SLN formulations significantly improve drug pharmacokinetics, increasing the brain area under the curve (AUC) compared with conventional formulations. Reported brain targeting efficiency (BTE%) with drug targeting index (DTI) values confirmed preferential nose-to-brain transport and improved CNS exposure. The improved targeting efficiency is attributed to the mucoadhesive nature of chitosan, enhanced permeability, and prolonged nasal residence time of SLNs. Conclusion: Chitosan-coated Solid Lipid Nanoparticles (SLNs) are an interesting candidate for a nanocarrier system to deliver drugs through the intranasal route into the CNS (Central Nervous System). Future research should emphasize Quality by Design (QbD)-based optimization, advanced surface modifications for targeted delivery, and comprehensive safety and clinical validation to support successful translation into clinical practice.
Downloads
References
Che J, Sun Y, Deng Y, Zhang J. Blood-brain barrier disruption: a culprit of cognitive decline? Fluids Barriers CNS, 21(1), 63 (2024) https://doi.org/10.1186/s12987-024-00563-3
Yu T, Wang Z, Chen Y, Xiang Y, Wu M, et al. Blood–brain barrier dysfunction in CNS diseases: paying attention to pericytes. CNS Neurosci Ther, 31(5), e70422 (2025) https://doi.org/10.1111/cns.70422
Hang Z, Zhou L, Xing C, Wen Y, Du H. The blood-brain barrier is a key bridge to treat neurodegenerative diseases. Ageing Res Rev, 91, 102070 (2023) https://doi.org/10.1016/j.arr.2023.102070
Lau K, Kotzur R, Richter F. Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy. Transl Neurodegener, 13(1), 37 (2024) https://doi.org/10.1186/s40035-024-00430-z
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet, 397, 1577–1590 (2021) https://doi.org/10.1016/S0140-6736(20)32205-4
Wu X, Zang R, Qiu Y, Zhang Y, Peng J, Cheng Z, et al. Intranasal drug delivery technology in the treatment of central nervous system diseases: challenges, advances, and future research directions. Pharmaceutics, 17(6), 775 (2025) https://doi.org/10.3390/pharmaceutics17060775
Alonso CW, McElhatton F, O’Mahony B, Campbell M, Pollak TA, Stokes PR. The blood-brain barrier in bipolar disorders: a systematic review. J Affect Disord, 361, 434–444 (2024) https://doi.org/10.1016/j.jad.2024.06.032
Omidian H, Gill EJ, Dey Chowdhury S, Cubeddu LX. Chitosan nanoparticles for intranasal drug delivery. Pharmaceutics, 16(6), 746 (2024) https://doi.org/10.3390/pharmaceutics16060746
Costa CP, Moreira JN, Lobo JM, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B, 11(4), 925–940 (2021) https://doi.org/10.1016/j.apsb.2021.02.012
Chin LY, Tan JYP, Choudhury H, Pandey M, Sisinthy SP, Gorain B. Development and optimization of chitosan coated nanoemulgel of telmisartan for intranasal delivery: a comparative study. J Drug Deliv Sci Technol, 62, 102341 (2021) https://doi.org/10.1016/j.jddst.2021.102341
Zhang YB, Xu D, Bai L, Zhou YM, Zhang H, Cui YL. A review of non-invasive drug delivery through respiratory routes. Pharmaceutics, 14(9), 1974 (2022) https://doi.org/10.3390/pharmaceutics14091974
Koo J, Lim C, Oh KT. Recent advances in intranasal administration for brain-targeting delivery. Int J Nanomedicine, 19, 1767–1807 (2024) https://doi.org/10.2147/IJN.S439181
Butola M, Nainwal N. Non-invasive techniques of nose to brain delivery using nanoparticulate carriers: hopes and hurdles. AAPS PharmSciTech, 25(8), 256 (2024) https://doi.org/10.1208/s12249-024-02946-z
Agosti E, Zeppieri M, Antonietti S, Battaglia L, Ius T, Gagliano C, et al. Navigating the nose-to-brain route: lipid-based nanocarriers for CNS disorders. Pharmaceutics, 16(3), 329 (2024) https://doi.org/10.3390/pharmaceutics16030329
Gandhi S, Shastri DH, Shah J, Nair AB, Jacob S. Nasal delivery to the brain: harnessing nanoparticles for effective drug transport. Pharmaceutics, 16(4), 481 (2024) https://doi.org/10.3390/pharmaceutics16040481
Ibrahim RM, Teaima M, El-Nabarawi M, Badawi NM. Intranasal delivery of chitosan-based nanoparticles for neurodegenerative disorders. J Drug Deliv Sci Technol, 99, 105885 (2024) https://doi.org/10.1016/j.jddst.2024.105885
Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, Jiang G, et al. Intranasal drug delivery: the interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev, 207, 115196 (2024) https://doi.org/10.1016/j.addr.2024.115196
Das M, Sarma A, Baruah H, Basak D. Insight into central nervous system targeted nanostructured lipid carriers via the nose-to-brain pathway. RSC Pharm, 1(5), 904–927 (2024) https://doi.org/10.1039/D4PM00057A
Sidhaye I, Karadagi A, Harish KH, Meti V, Dasankoppa FS, Swamy AH. Recent advances in intranasal delivery with lipid nanoparticles for brain targeting. J Young Pharm, 17(1), 54–61 (2025) https://doi.org/10.5530/jyp.20251166
Wang S, Sun Y, Zhang J, Cui X, Xu Z, Ding D, et al. Astragalus polysaccharides/chitosan microspheres for nasal delivery: preparation, optimization, characterization, and pharmacodynamics. Front Pharmacol, 11, 230 (2020) https://doi.org/10.3389/fphar.2020.00230
Shim S, Yoo HS. The application of mucoadhesive chitosan nanoparticles in nasal drug delivery. Mar Drugs, 18(12), 605 (2020) https://doi.org/10.3390/md18120605
Wei S, Zhai Z, Kong X, Wu C, Zhu B, Zhao Z, et al. Strategies to enhance efficiency of intranasal drug delivery. Int J Pharm, 676, 125584 (2025) https://doi.org/10.1016/j.ijpharm.2025.125584
Khunt D, Misra M. Anatomical and physiological aspects of the nose and brain. In: Pathak Y, Sutariya V, Hirani A (eds). Direct Nose-to-Brain Drug Delivery. Elsevier, 3–14 (2021) https://doi.org/10.1016/B978-0-12-822522-6.00029-1
Shrisunder N, Dhakad PK, Gilhotra R. Development of a fast-acting nanosuspension nasal drop using a novel co-processed polymer for migraine relief. J Appl Pharm Res, 13(3), 164–178 (2025) https://doi.org/10.69857/joapr.v13i3.940
Kaliniak S, Fiedoruk K, Spałek J, Piktel E, Durnaś B, Góźdź S, et al. Remodeling of paranasal sinuses mucosa functions in response to biofilm-induced inflammation. J Inflamm Res, 17, 1295–1323 (2024) https://doi.org/10.2147/JIR.S443420
Elwany S, Askar M. Nasal physiology and functions. Rhinology Review. Springer Nature, 31–36 (2023) https://doi.org/10.1007/978-3-031-08794-3
Hsu DW, Suh JD. Anatomy and physiology of nasal obstruction. Otolaryngol Clin North Am, 51, 853–865 (2018) https://doi.org/10.1016/j.otc.2018.05.001
Inthavong K, Wen J, Tian G. Aerodynamic and heat and moisture transfer in the normal nasal cavity. Respir Physiol Neurobiol, 280, 103480 (2020) https://doi.org/10.1016/j.resp.2020.103480
Han SA, Kim JK, Cho DY, Patel ZM, Rhee CS. The olfactory system: basic anatomy and physiology. Clin Exp Otorhinolaryngol, 16(4), 308–316 (2023) https://doi.org/10.21053/ceo.2023.00185
Huang Q, Chen X, Yu S, Gong G, Shu H. Research progress in brain-targeted nasal drug delivery. Front Aging Neurosci, 15, 1341295 (2024) https://doi.org/10.3389/fnagi.2023.1341295
Nguyen LT, Duong VA. Nose-to-brain drug delivery. Encyclopedia, 5, 91 (2025) https://doi.org/10.3390/encyclopedia5030091
Shusterman D. Trigeminal function in sino-nasal health and disease. Biomedicines, 11(7), 1778 (2023) https://doi.org/10.3390/biomedicines11071778
Terrier LM, Hadjikhani N, Destrieux C. The trigeminal pathways. J Neurol, 269(6), 3443–3460 (2022) https://doi.org/10.1007/s00415-022-11002-4
Akita T, Oda Y, Kimura R, Nagai M, Tezuka A, Shimamura M, et al. Trigeminal axons involvement in nose-to-brain delivery. J Control Release, 351, 573–580 (2022) https://doi.org/10.1016/j.jconrel.2022.09.047
Drath I, Richter F, Feja M. Nose-to-brain drug delivery: from bench to bedside. Transl Neurodegener, 14(1), 23 (2025) https://doi.org/10.1186/s40035-025-00481-w
Morim E, Sarmento B, Pacheco C. Nanocarrier based intranasal drug delivery for enhanced neurological disorders treatment. Drug Deliv Transl Res, 16(3), 761–779 (2026) https://doi.org/10.1007/s13346-025-02019-z
Li Y, Wang C, Zong S, Qi J, Dong X, Zhao W, et al. The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles. J Biomed Nanotechnol, 15(4), 686–702 (2019) https://doi.org/10.1166/jbn.2019.2724
Jayoush AR, Hassan HA, Asiri H, Jafar M, Saeed R, Harati R, et al. Niosomes for nose-to-brain delivery in neurodegenerative diseases. J Drug Deliv Sci Technol, 89, 105007 (2023) https://doi.org/10.1016/j.jddst.2023.105007
Hafner A. Advances in development, characterization and application of nasal drug delivery systems. Pharmaceutics, 14(8), 1562 (2022) https://doi.org/10.3390/pharmaceutics14081562
Pal R, Pandey P, Koli M, Srivastava K, Tiwari V, Gaur AK, et al. Exploring nasopulmonary drug delivery systems. J Drug Deliv Ther, 14(3), 126–136 (2024) https://doi.org/10.22270/jddt.v14i3.6444
Uemura N, Onishi T, Mitaniyama A, Kaneko T, Ninomiya K, Nakamura K, et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig, 25(3), 199–208 (2005) https://doi.org/10.2165/00044011-200525030-00006
Obaidi M, Offman E, Messina J, Carothers J, Djupesland PG, Mahmoud RA. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. Headache, 53(8), 1323–1333 (2013) https://doi.org/10.1111/head.12167
Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet, 41(11), 801–811 (2002) https://doi.org/10.2165/00003088-200241110-00002
Alwahsh W, Sahudin S, Alkhatib H, Bostanudin MF, Alwahsh M. Chitosan-based nanocarriers for pulmonary and intranasal drug delivery systems: a comprehensive overview. Curr Drug Targets, 25(7), 492–511 (2024) https://doi.org/10.2174/0113894501301747240417103321
Aderibigbe BA, Naki T. Chitosan-based nanocarriers for nose to brain delivery. Appl Sci, 9(11), 2219 (2019) https://doi.org/10.3390/app9112219
Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci, 22(17), 9652 (2021) https://doi.org/10.3390/ijms22179652
Chatzitaki AT, Jesus S, Karavasili C, Andreadis D, Fatouros DG, Borges O. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride. Int J Pharm, 589, 119776 (2020) https://doi.org/10.1016/j.ijpharm.2020.119776
Popescu R, Ghica MV, Dinu-Pîrvu CE, Anuța V, Lupuliasa D, Popa L. New opportunity to formulate intranasal vaccines and drug delivery systems based on chitosan. Int J Mol Sci, 21(14), 5016 (2020) https://doi.org/10.3390/ijms21145016
Kumari R, Vivekanand V, Pareek N. Chitin and chitosan derivatives and its nanocomposites: therapeutic applications. In: Biotechnological Advances in Chitin and Chitosan Based Biocomposites. Springer, 173–195 (2025) https://doi.org/10.1007/978-981-96-6354-5_9
Gao X, Liu N, Wang Z, Gao J, Zhang H, Li M, et al. Development and optimization of chitosan nanoparticle-based intranasal vaccine carrier. Molecules, 27(1), 204 (2021) https://doi.org/10.3390/molecules27010204
Gonciarz W, Balcerczak E, Brzeziński M, Jeleń A, Pietrzyk-Brzezińska AJ, Narayanan VH, et al. Chitosan-based formulations for therapeutic applications. J Biomed Sci, 32(1), 62 (2025) https://doi.org/10.1186/s12929-025-01161-7
Collado-González M, González Espinosa Y, Goycoolea FM. Interaction between chitosan and mucin: fundamentals and applications. Biomimetics, 4(2), 32 (2019) https://doi.org/10.3390/biomimetics4020032
Prabakaran A, Rakshit D, Patel I, Susanna KJ, Mishra A, Radhakrishnanand P, et al. Chitosan-coated nanostructured lipid carriers for intranasal delivery of sinapic acid in Alzheimer’s disease. Int J Biol Macromol, 305, 141136 (2025) https://doi.org/10.1016/j.ijbiomac.2025.141136
Paradowska-Stolarz A, Mikulewicz M, Laskowska J, Karolewicz B, Owczarek A. The importance of chitosan coatings in dentistry. Mar Drugs, 21(12), 613 (2023) https://doi.org/10.3390/md21120613
Arshad N, Khan M, Waseem M, Afzal M, Alarifi A, Saleem RS. Functionalization of surfactant templated magnetite by chitosan and PEGylated chitosan. J Saudi Chem Soc, 27(6), 101744 (2023) https://doi.org/10.1016/j.jscs.2023.101744
Maher R, Moreno-Borrallo A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics, 15(3), 746 (2023) https://doi.org/10.3390/pharmaceutics15030746
Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Control Release, 190, 189–200 (2014) https://doi.org/10.1016/j.jconrel.2014.05.003
Torres J, Silva R, Farias G, Sousa Lobo JM, Ferreira DC, Silva AC. Enhancing acute migraine treatment using lipid nanoparticles for the nose-to-brain route. Pharmaceutics, 16(10), 1297 (2024) https://doi.org/10.3390/pharmaceutics16101297
Shah P, Lalan M, Barve K. Intranasal delivery of nucleic acid-based therapeutics for CNS disorders. Front Pharmacol, 13, 974666 (2022) https://doi.org/10.3389/fphar.2022.974666
Pinheiro RG, Coutinho AJ, Pinheiro M, Neves AR. Nanoparticles for targeted brain drug delivery: what do we know? Int J Mol Sci, 22(21), 11654 (2021) https://doi.org/10.3390/ijms222111654
Susa F, Arpicco S, Pirri CF, Limongi T. An overview on the physiopathology of the blood–brain barrier and lipid-based nanocarriers for CNS delivery. Pharmaceutics, 16(7), 849 (2024) https://doi.org/10.3390/pharmaceutics16070849
Antunes JL, Amado J, Veiga F, Paiva-Santos AC, Pires PC. Intranasal delivery strategies for antidepressant and anxiolytic drugs. Pharmaceutics, 15(3), 998 (2023) https://doi.org/10.3390/pharmaceutics15030998
Chen Y, Liu L. Modern methods for delivery of drugs across the blood–brain barrier. Adv Drug Deliv Rev, 64(7), 640–665 (2012) https://doi.org/10.1016/j.addr.2011.11.010
Islam S, Ahmed MM, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery. Results Surf Interfaces, 19, 100529 (2025) https://doi.org/10.1016/j.rsurfi.2025.100529
Ly PD, Ly KN, Phan HL, Nguyen HH, Duong VA, Nguyen HV. Recent advances in surface decoration of nanoparticles in drug delivery. Front Nanotechnol, 6, 1456939 (2024) https://doi.org/10.3389/fnano.2024.1456939
Abdelkawi A, Slim A, Zinoune Z, Pathak Y. Surface modification of metallic nanoparticles for targeting drugs. Coatings, 13(9), 1660 (2023) https://doi.org/10.3390/coatings13091660
Kranti P, Ramanlal K, Madhuri K, Vinayak Z. A review on nanoparticles drug delivery system. J Drug Deliv Ther, 11(4), 101–104 (2021) https://doi.org/10.22270/jddt.v11i4.4865
Yusuf A, Almotairy AR, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as drug delivery systems. Polymers, 15(7), 1596 (2023) https://doi.org/10.3390/polym15071596
Seo MW, Park TE. Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases. Biomed Eng Lett, 11(3), 211–216 (2021) https://doi.org/10.1007/s13534-021-00198-5
Senanayake D, Yapa P, Dabare S, Munaweera I. Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery. RSC Adv, 15(32), 25910–25928 (2025) https://doi.org/10.1039/D5RA03578C
Yan X, Chen Q. Polyamidoamine dendrimers: brain-targeted drug delivery systems in glioma therapy. Polymers, 16(14), 2022 (2024) https://doi.org/10.3390/polym16142022
Bharadwaj P, Roullin VG, Chain JL. Crossing the blood–brain barrier: advances in dendrimer-based nanocarriers. Nanoscale, 17(40), 23202–23227 (2025) https://doi.org/10.1039/d5nr02548f
Dai Y, Min Y, Zhou L, Cheng L, Ni H, Yang Y, et al. Brain-targeting redox-sensitive micelles for glioblastoma therapy. Nanomedicine, 61, 102772 (2024) https://doi.org/10.1016/j.nano.2024.102772
Kaur P, Rajput A, Singh D, Singh G, Mehra A, Kaur S, et al. Polymeric micelles for brain drug delivery systems. Curr Drug Deliv, 21(1), 65–79 (2024) https://doi.org/10.2174/1567201820666230413082352
Amiri M, Jafari S, Kurd M, Mohamadpour H, Khayati M, Ghobadinezhad F, et al. Engineered lipid nanoparticles as blood–brain barrier transmitters. ACS Chem Neurosci, 12(24), 4475–4490 (2021) https://doi.org/10.1021/acschemneuro.1c00540
Mehrdadi S. Drug delivery of solid lipid nanoparticles to target brain tumors. Adv Pharm Bull, 13(3), 512 (2022) https://doi.org/10.34172/apb.2023.062
Zheng Y, Cui L, Lu H, Liu Z, Zhai Z, Wang H, et al. Nose to brain delivery using solid lipid nanoparticles and nanostructured lipid carriers. Int J Nanomedicine, 19, 12342–12368 (2024) https://doi.org/10.2147/IJN.S497480
Fernandes F, Dias-Teixeira M, Delerue-Matos C, Grosso C. Lipid-based nanoparticles as carriers of neuroprotective drugs. Nanomaterials, 11(3), 563 (2021) https://doi.org/10.3390/nano11030563
Khare P, Edgecomb SX, Hamadani CM, Tanner EE, Manickam DS. Lipid nanoparticle-mediated drug delivery to the brain. Adv Drug Deliv Rev, 197, 114861 (2023) https://doi.org/10.1016/j.addr.2023.114861
Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, et al. Solid lipid nanoparticles targeting the brain through BBB. Pharmaceutics, 13(8), 1183 (2021) https://doi.org/10.3390/pharmaceutics13081183
Al-Sayadi GM, Verma A, Choudhary Y, Sandal P, Patel P, Singh D, et al. Solid lipid nanoparticles (SLNs): advancements in modification strategies toward drug delivery vehicle. Pharm Nanotechnol, 11(2), 138–154 (2023) https://doi.org/10.2174/2211738511666221026163303
Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A recent update: solid lipid nanoparticles for effective drug delivery. Adv Pharm Bull, 12(1), 17 (2021) https://doi.org/10.34172/apb.2022.007
Lavate MA, Karpe ST, Biradar SN, Bhandare MR. Solid lipid nanoparticles: a promising drug delivery method to get greater bioavailability. World J Biol Pharm Health Sci, 14, 72–78 (2023) https://doi.org/10.30574/wjbphs.2023.14.2.0104
Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid lipid nanoparticles vs nanostructured lipid carriers: a comparative review. Pharmaceutics, 15(6), 1593 (2023) https://doi.org/10.3390/pharmaceutics15061593
Alloush T, Demiralp B. Formulation strategies for cyclodextrin-enhanced solid lipid nanoparticles and nanostructured lipid carriers. Int J Mol Sci, 26(13), 6509 (2025) https://doi.org/10.3390/ijms26136509
Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis, 11(1), 159 (2012) https://doi.org/10.1186/1476-511X-11-159
Cunha S, Costa CP, Moreira JN, Lobo JM, Silva AC. Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions. Nanomedicine, 28, 102206 (2020) https://doi.org/10.1016/j.nano.2020.102206
Hidayat AF, Wardhana YW, Suwendar S, Mohammed AF, Mahmoud SA, Elamin KM, et al. QbD-driven optimization of lipid nanoparticles for oral drug delivery. Int J Nanomedicine, 20, 8611–8631 (2025) https://doi.org/10.2147/IJN.S534137
Onugwu AL, Attama AA, Nnamani PO, Onugwu SO, Onuigbo EB, Khutoryanskiy VV. Development and optimization of chitosan coated solid lipid nanoparticles for ocular drug delivery of ciprofloxacin. J Drug Deliv Sci Technol, 74, 103527 (2022) https://doi.org/10.1016/j.jddst.2022.103527
Jia Z, Li J, Gao L, Yang D, Kanaev A. Dynamic light scattering: a powerful tool for in situ nanoparticle sizing. Colloids Interfaces, 7(1), 15 (2023) https://doi.org/10.3390/colloids7010015
Sikhondze SS, Makoni PA, Walker RB, Khamanga SM. Chitosan-coated SLN for ocular delivery of metronidazole. Pharmaceutics, 15(7), 1855 (2023) https://doi.org/10.3390/pharmaceutics15071855
Bhattacharjee S. DLS and zeta potential—what they are and what they are not. J Control Release, 235, 337–351 (2016) https://doi.org/10.1016/j.jconrel.2016.06.017
Sohaib M, Shah SU, Khan NR, Irfan MM, Niazi ZR, Alqahtani AA, et al. Physicochemical characterization of chitosan-decorated finasteride solid lipid nanoparticles for skin drug delivery. Biomed Res Int, 2022, 7792180 (2022) https://doi.org/10.1155/2022/7792180
Filippov SK, Khusnutdinov R, Murmiliuk A, Inam W, Zakharova LY, Zhang H, et al. Dynamic light scattering and TEM in drug delivery nanoparticle characterization. Mater Horiz, 10(12), 5354–5370 (2023) https://doi.org/10.1039/D3MH00717K
Saini S, Sharma T, Jain A, Kaur H, Katare OP, Singh B. Chitosan-coated solid lipid nanoparticles of ferulic acid for Alzheimer’s disease. Colloids Surf B Biointerfaces, 205, 111828 (2021) https://doi.org/10.1016/j.colsurfb.2021.111838
Hassan DM, El-Kamel AH, Allam EA, Bakr BA, Ashour AA. Chitosan-coated nanostructured lipid carriers for brain delivery of Tanshinone IIA. Drug Deliv Transl Res, 14(2), 400–417 (2024) https://doi.org/10.1007/s13346-023-01407-7
Martínez EO, Hernandez ME, Castillo-González J, González-Rey E, Martinez MA. Dopamine-loaded chitosan-coated SLN as nanocarriers to CNS. Neuropharmacology, 249, 109871 (2024) https://doi.org/10.1016/j.neuropharm.2024.109871
Salat D, Tolosa E. Levodopa in the treatment of Parkinson's disease. J Parkinsons Dis, 3(3), 255–269 (2013) https://doi.org/10.3233/JPD-130186
Pira A, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson’s disease. Eur J Neurol, 16(9), 982–989 (2009) https://doi.org/10.1111/j.1468-1331.2009.02697.x
Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. Nose-to-brain drug delivery using nanoparticles. Appl Mater Today, 29, 101631 (2022) https://doi.org/10.1016/j.apmt.2022.101631
Nguyen TT, Maeng HJ. Pharmacokinetics and pharmacodynamics of intranasal lipid nanoparticles. Pharmaceutics, 14(3), 572 (2022) https://doi.org/10.3390/pharmaceutics14030572
Gharibkandi NA, Molavipordanjani S, Akbari J, Hosseinimehr SJ. Pharmacokinetic evaluation of radiolabeled solid lipid nanoparticles. Curr Drug Metab, 20(13), 1044–1052 (2019) https://doi.org/10.2174/1389200220666191112145808
Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. Chitosan coated nanostructured lipid carriers for brain delivery of proteins. Colloids Surf B Biointerfaces, 134, 304–313 (2015) https://doi.org/10.1016/j.colsurfb.2015.06.054
Sreeharsha N, Prasanthi S, Rao GS, Gajula LR, Biradar N, Goudanavar P, et al. Formulation optimization of chitosan coated SLN of griseofulvin. Eur J Pharm Sci, 204, 106951 (2025) https://doi.org/10.1016/j.ejps.2024.106951
Raghunath I, Koland M, Saoji SD, Bukke SP, Deshpande NS, Augustin V, et al. Effects of piperine on insulin loaded SLN pharmacokinetics. Sci Rep, 15(1), 22771 (2025) https://doi.org/10.1038/s41598-025-05137-3
Kenechukwu FC, Ugwu KC, Offorbuike CS, Ojukwu EM, Gugu TH, Eze RE, et al. Chitosan-coated SLN for oral delivery of artemether. BMC Chem, 19(1), 64 (2025) https://doi.org/10.1186/s13065-025-01422-4
Noorulla KM, Yasir M, Muzaffar F, Ghoneim MM, Almurshedi AS, Tura AJ, et al. Intranasal delivery of buspirone nanostructured lipid carriers. J Drug Deliv Sci Technol, 67, 102939 (2022) https://doi.org/10.1016/j.jddst.2021.102939
Alastal A, Kwaik AD, Malkawi AA, Baltzley S, Al-Ghananeem AM. Enhancing intranasal delivery of dihydroergotamine utilizing chitosan nanoparticles. J Clin Pharm Ther, 2023, 2284371 (2023) https://doi.org/10.1155/2023/2284371
Khan A, Imam SS, Aqil M, Ahad A, Sultana Y, Ali A, et al. Brain targeting of temozolomide via the intranasal route using lipid nanoparticles. Mol Pharm, 13(11), 3773–3782 (2016) https://doi.org/10.1021/acs.molpharmaceut.6b00586
Chauhan MB, Chauhan NB. Brain uptake of neurotherapeutics after intranasal versus intraperitoneal delivery in mice. J Neurol Neurosurg, 2(1), 91 (2015) https://doi.org/10.19104/jnn.2015.91
Silki, Sinha VR. Enhancement of oral bioavailability of aripiprazole with solid lipid nanoparticles. AAPS PharmSciTech, 19(3), 1264–1273 (2018) https://doi.org/10.1208/s12249-017-0944-5
Fatouh AM, Elshafeey AH, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery. Drug Des Devel Ther, 11, 1815–1825 (2017) https://doi.org/10.2147/DDDT.S102500
Crowe TP, Hsu WH. Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics, 14(3), 629 (2022) https://doi.org/10.3390/pharmaceutics14030629
Villar-Gómez N, Ojeda-Hernandez DD, López-Muguruza E, García-Flores S, Bonel-García N, Benito-Martín MS, et al. Nose-to-brain delivery for stem cell therapy in neurological disorders. Cells, 11(19), 3095 (2022) https://doi.org/10.3390/cells11193095
Madden S, Carrazana E, Rabinowicz AL. Optimizing absorption for intranasal delivery targeting CNS. Pharmaceutics, 15(8), 2119 (2023) https://doi.org/10.3390/pharmaceutics15082119
Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges. Drug Deliv Transl Res, 12(4), 735–757 (2022) https://doi.org/10.1007/s13346-020-00891-5
Egba SI, Edeh MO, Uchenna NO, Igwe MC, Ogbodo JO. Nasal delivery of phytochemicals using nanocarriers. Int J Nanomedicine, 20, 15017–15041 (2025) https://doi.org/10.2147/IJN.S564106
Tiwari P, Prajapati SK, Dixit V, Raza MA, Gupta SK, Sharma M. Recent advancements in nanoparticle drug delivery via nasal route. Neurol Argent, 17(3), 143–152 (2025) https://doi.org/10.1016/j.neuarg.2025.05.003
Rigaut C, Deruyver L, Niesen M, Vander Ghinst M, Goole J, Lambert P, et al. Anatomical features influencing nose-to-brain delivery. Pharmaceutics, 15(12), 2661 (2023) https://doi.org/10.3390/pharmaceutics15122661
Cui L, Yang Y, Hao Y, Zhao H, Zhang Y, Wu T, et al. Nanotechnology-based therapeutics for airway inflammatory diseases. Clin Rev Allergy Immunol, 68(1), 12 (2025) https://doi.org/10.1007/s12016-024-09019-w
Dighe S, Jog S, Momin M, Sawarkar S, Omri A. Intranasal nanotechnology for Alzheimer’s disease management. Pharmaceutics, 16(1), 58 (2023) https://doi.org/10.3390/pharmaceutics16010058
Pandey P, Pandey S, Cabot PJ, Wallwork B, Panizza BJ, Parekh HS. Toxicity evaluation of dexamethasone nasal gelling systems. Saudi Pharm J, 27(7), 914–919 (2019) https://doi.org/10.1016/j.jsps.2019.06.005
Trows S, Wuchner K, Spycher R, Steckel H. Analytical challenges and regulatory requirements for nasal drug products. Pharmaceutics, 6(2), 195–219 (2014) https://doi.org/10.3390/pharmaceutics6020195
Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol, 56(3), 290–299 (2010) https://doi.org/10.1016/j.yrtph.2009.09.015
Protopapa C, Siamidi A, Pavlou P, Vlachou M. Excipients used for modified nasal drug delivery. Materials, 15(19), 6547 (2022) https://doi.org/10.3390/ma15196547
Cipolla D, Gruenloh CJ, Kadrichu N, Kuehl PJ, Mao L, Li BV, et al. Inhalable and nasal biologics: analytical and regulatory considerations. J Aerosol Med Pulm Drug Deliv, 38, 123–138 (2025) https://doi.org/10.1089/jamp.2024.0058
Patel A, Pandey P. Investigation of potential efficacy of nanospanlastic vesicular drug delivery system for targeting the brain: formulation, characterization, and in vivo studies. Journal of Applied Pharmaceutical Research, 13(4), 132–142 (2025) https://doi.org/10.69857/joapr.v13i4.1340
Fortuna A, Schindowski K, Sonvico F. Intranasal drug delivery: challenges and opportunities. Front Pharmacol, 13, 868986 (2022) https://doi.org/10.3389/fphar.2022.868986
Loureiro JA, Ramalho MJ, Carmo Pereira Md. Immuno-nanocarriers for brain delivery. Nanomedicine, 15, 543–545 (2020) https://doi.org/10.2217/nnm-2019-0402
Dawoud MH, Mannaa IS, Abdel-Daim A, Sweed NM. Artificial intelligence with QbD in lecithin/chitosan nanoparticles formulation. AAPS PharmSciTech, 24(6), 169 (2023) https://doi.org/10.1208/s12249-023-02609-5
Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, et al. Scale-up methods for preparation of solid lipid nanoparticles. Pharmaceutics, 14(9), 1886 (2022) https://doi.org/10.3390/pharmaceutics14091886
Abdel-Bar HM, Abdel-Reheem AY, Awad GA, Mortada ND. Evaluation of brain targeting of nasally administered nanostructured carriers of clonazepam. J Pharm Pharm Sci, 16(3), 456–469 (2013) https://doi.org/10.18433/J30S31
Nguyen TT, Duong VA. Advancements in nanocarrier systems for nose-to-brain drug delivery. Pharmaceuticals, 18(5), 615 (2025) https://doi.org/10.3390/ph18050615
Zafar A, Alsaidan OA, Alruwaili NK, Imam SS, Yasir M, Alharbi KS, et al. Intranasal surface engineered nanostructured lipid carriers of rotigotine. Int J Pharm, 627, 122232 (2022) https://doi.org/10.1016/j.ijpharm.2022.122232
Published
How to Cite
Issue
Section
Copyright (c) 2026 Samruddhi Rakshe, Manisha Lalan, Pranav Shah, Dikshitkumar Modi, Vrutti Parmar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
